Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a Potent C-C chemokine receptor-1 antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 2, 2010, Pages 562-568

  Lu, Chuang ^a   Balani, Suresh K ^a   Qian, Mark G ^a   Prakash, Shimoga R ^a   Ducray, Patricia S ^a   Von Moltke, Lisa L ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CYTOCHROME P450 3A; FLUCONAZOLE; KETOCONAZOLE; MIDAZOLAM; MLN 3897; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS;

ADULT; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; FLUCONAZOLE; HEPATOCYTES; HUMANS; KETOCONAZOLE; MALE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; RECEPTORS, CCR1;

EID: 76749099255     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.161893     Document Type: Article

References (17)

1. Bachmann KA (2006) Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise. Curr Drug Metab 7:1-14.
2. 50 and inhibitor concentration. Curr Drug Metab 5:147-156.
3. Brunton LL, Lazo JS, and Park KL (2006) Goodman & Gilman's The Pharmacocological Basis of Therapeutics, McGraw-Hill, New York.
4. Cook CS, Berry LM, and Burton E (2004) Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data. Xenobiotica 34:215-228.
5. Galetin A and Houston JB (2009) Inhibition of drug metabolism enzymes in gastro-intestinal tract and its influence on the drug-drug interaction prediction, in Enzyme Inhibition in Drug Discovery and Development: The Good and the Bad (Lu C and Li AP eds) pp 519-557, Wiley Press, Hoboken, NJ.
6. Galetin A, Ito K, Hallifax D, and Houston JB (2006) CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interaction prediction, J Pharmacol Exp Ther 314:180-190.
7. Greenblatt DJ and von Moltke LL (2008) Gender has a small statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol 48:1350-1355.
8. Ito K, Brown HS, and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486.
9. Lu C, Berg C, Prakash SR, Lee FW, and Balani SK (2008a) Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole. Drug Metab Dispos 36:1261-1266.
10. Lu C, Hatsis P, Berg C, Lee FW, and Balani SK (2008b) Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole. Drug Metab Dispos 36:1255-1260.
11. Lu C, Miwa GT, Prakash SR, Gan LS, and Balani SK (2007) A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome P450 phenotyping data. Drug Metab Dispos 35:79-85.
12. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
13. Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, and Raunio H (1998) Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobioteca 28:1203-1253.
14. Rostami-Hodjegan A and Tucker GT (2004) "In silico" simulation to assess the "in vivo" consequences of "in vitro" metabolic drug-drug interactions. Drug Discov Today Tech 1:441-448.
15. Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, and Sugiyama Y (2003) Function of uptake transporters for taurocholate and estradiol 17beta-D-glucuronide in cryo-preserved human hepatocytes. Drug Metab Pharmacokinet 18:33-41.
16. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
17. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (2000) Effects of the anti-fungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmocokinet 38:111-180.